FDA Setback for Outlook Therapeutics’ ONS-5010
The FDA asks for more proof, pushing Outlook’s ophthalmic bevacizumab ambitions back into review mode. Another lap around the regulatory…
latest posts
The FDA asks for more proof, pushing Outlook’s ophthalmic bevacizumab ambitions back into review mode. Another lap around the regulatory…